Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,281 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rationale and design of an investigator-initiated, multicenter, prospective, placebo-controlled, double-blind, randomized trial to evaluate the effects of finerenone on vascular stiffness and cardiorenal biomarkers in type 2 diabetes and chronic kidney disease (FIVE-STAR).
Tanaka A, Shibata H, Imai T, Yoshida H, Miyazono M, Takahashi N, Fukuda D, Okada Y, Teragawa H, Suwa S, Kida K, Moroi M, Taguchi I, Toyoda S, Shimabukuro M, Tanabe K, Tanaka K, Nangaku M, Node K; FIVE-STAR trial investigators. Tanaka A, et al. Among authors: imai t. Cardiovasc Diabetol. 2023 Jul 31;22(1):194. doi: 10.1186/s12933-023-01928-y. Cardiovasc Diabetol. 2023. PMID: 37525257 Free PMC article. Clinical Trial.
Effect of canagliflozin on N-terminal pro-brain natriuretic peptide in patients with type 2 diabetes and chronic heart failure according to baseline use of glucose-lowering agents.
Tanaka A, Toyoda S, Imai T, Shiina K, Tomiyama H, Matsuzawa Y, Okumura T, Kanzaki Y, Onishi K, Kiyosue A, Nishino M, Sakata Y, Node K; CANDLE trial investigators. Tanaka A, et al. Among authors: imai t. Cardiovasc Diabetol. 2021 Sep 3;20(1):175. doi: 10.1186/s12933-021-01369-5. Cardiovasc Diabetol. 2021. PMID: 34479543 Free PMC article. Clinical Trial.
Effects of canagliflozin on NT-proBNP stratified by left ventricular diastolic function in patients with type 2 diabetes and chronic heart failure: a sub analysis of the CANDLE trial.
Kusunose K, Imai T, Tanaka A, Dohi K, Shiina K, Yamada T, Kida K, Eguchi K, Teragawa H, Takeishi Y, Ohte N, Yamada H, Sata M, Node K; CANDLE Trial Investigators. Kusunose K, et al. Among authors: imai t. Cardiovasc Diabetol. 2021 Sep 14;20(1):186. doi: 10.1186/s12933-021-01380-w. Cardiovasc Diabetol. 2021. PMID: 34521417 Free PMC article. Clinical Trial.
Mediators of the effects of canagliflozin on N-terminal pro-brain natriuretic peptide concentration: An exploratory mediation analysis of the randomized CANDLE trial.
Tanaka A, Imai T, Suzuki M, Hiramitsu S, Takahashi N, Kadokami T, Kiyosue A, Nishino M, Sakata Y, Node K; CANDLE trial investigators. Tanaka A, et al. Among authors: imai t. Diabetes Obes Metab. 2022 May;24(5):962-965. doi: 10.1111/dom.14656. Epub 2022 Feb 21. Diabetes Obes Metab. 2022. PMID: 35112456 Clinical Trial. No abstract available.
Body fluid regulation via chronic inhibition of sodium-glucose cotransporter-2 in patients with heart failure: a post hoc analysis of the CANDLE trial.
Fujiki S, Tanaka A, Imai T, Shimabukuro M, Uehara H, Nakamura I, Matsunaga K, Suzuki M, Kashimura T, Minamino T, Inomata T, Node K; CANDLE Trial Investigators. Fujiki S, et al. Among authors: imai t. Clin Res Cardiol. 2023 Jan;112(1):87-97. doi: 10.1007/s00392-022-02049-4. Epub 2022 Jun 22. Clin Res Cardiol. 2023. PMID: 35729430 Clinical Trial.
Association between serum insulin levels and heart failure-related parameters in patients with type 2 diabetes and heart failure treated with canagliflozin: a post-hoc analysis of the randomized CANDLE trial.
Tanaka A, Imai T, Shimabukuro M, Taguchi I, Sezai A, Toyoda S, Watada H, Ako J, Node K; CANDLE trial investigators. Tanaka A, et al. Among authors: imai t. Cardiovasc Diabetol. 2022 Aug 8;21(1):151. doi: 10.1186/s12933-022-01589-3. Cardiovasc Diabetol. 2022. PMID: 35941584 Free PMC article. Clinical Trial.
Effect of canagliflozin on white blood cell counts in patients with type 2 diabetes and heart failure: A subanalysis of the randomized CANDLE trial.
Tanaka A, Imai T, Shimabukuro M, Nakamura I, Matsunaga K, Ozaki Y, Minamino T, Sata M, Node K; CANDLE trial investigators. Tanaka A, et al. Among authors: imai t. J Diabetes Investig. 2022 Dec;13(12):1990-1999. doi: 10.1111/jdi.13899. Epub 2022 Sep 16. J Diabetes Investig. 2022. PMID: 36114704 Free PMC article. Clinical Trial.
Canagliflozin reduces proteinuria by targeting hyperinsulinaemia in diabetes patients with heart failure: A post hoc analysis of the CANDLE trial.
Yamaguchi S, Shimabukuro M, Tanaka A, Imai T, Hiramitsu S, Takahashi N, Kadokami T, Ajioka M, Suzuki M, Node K; CANDLE Trial Investigators. Yamaguchi S, et al. Among authors: imai t. Diabetes Obes Metab. 2023 Feb;25(2):354-364. doi: 10.1111/dom.14876. Epub 2022 Oct 23. Diabetes Obes Metab. 2023. PMID: 36193841
Canagliflozin independently reduced plasma volume from conventional diuretics in patients with type 2 diabetes and chronic heart failure: a subanalysis of the CANDLE trial.
Shiina K, Tomiyama H, Tanaka A, Imai T, Hisauchi I, Taguchi I, Sezai A, Toyoda S, Dohi K, Kamiya H, Kida K, Anzai T, Chikamori T, Node K; CANDLE trial investigators. Shiina K, et al. Among authors: imai t. Hypertens Res. 2023 Feb;46(2):495-506. doi: 10.1038/s41440-022-01085-x. Epub 2022 Nov 15. Hypertens Res. 2023. PMID: 36380202
3,281 results